LOS ANGELES, CA / ACCESSWIRE / July 18, 2016 / Oxis International Inc. (OTC: OXIS and OXI.PA), a biotechnology company focused on immunotherapies for the treatment of cancer, is pleased to announce that the company will be holding an investor conference call on Thursday July 21, 2016 at 4:30PM EST.

The call will be hosted by BiotechStocks.com and company CEO Mr. Anthony Cataldo in preparation for a strong second half of 2016 after making large strides during the first two quarters of the year. Mr. Cataldo stated, "We are very optimistic for the outlook on the rest of this year. After the success we've seen already from our initial trials of OXS-1550, we feel that the future is looking bright. We are excited to be hosting our first investor conference call of the year to go over everything we've already gotten underway as well as what we plan to achieve before 2017. We're happy to have the team at Biotech Stock host this important call and will be looking forward to all questions we'll address during the call."

For those interested in attending the conference call and/or submitting questions, please refer to the following information:

Dial-in Number: 712.775.7031
Meeting ID Number: 576-591-822

Please direct all questions to oxis@biotechstocks.com. All questions should be submitted before 12PM EST on Thursday, July 21, 2016.

ABOUT OXIS INTERNATIONAL, INC.

Oxis International, Inc., through a wholly owned subsidiary, Oxis Biotech, Inc., develops innovative drugs focused on the treatment of cancer and other unmet medical needs. Oxis' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

About Biotech Stocks (www.BiotechStocks.com)

Biotech Stocks (www.biotechstocks.com) is your best resource for today's emerging biotech industry. Whether you're looking for the best biotech stocks to buy, biotech news, trends in biotech, articles within the biotech industry and so much more, BiotechStocks.com is your destination for it all. Our goal is to become the central hub for all who are seeking current Biotech Stock News as well as biotech industry, political and social news, articles, trends & overall insight, delivered in a way that we all can relate to.

FORWARD LOOKING STATEMENTS:

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company website: OXIS.COM

SOURCE: Oxis International, Inc.